torkinib (PP242)

News alerts, weekly reports and conference planners

Company:

Takeda, UCSF Medical Center

Drug class:

mTOR inhibitor, mTORC2 inhibitor

PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	PP242 Sensitive: D – Preclinical PP242 Sensitive : D	PP242 Sensitive: D – Preclinical PP242 Sensitive : D
HER-2 amplification	Breast Cancer	HER-2 amplification	Breast Cancer	PP242 Sensitive: D – Preclinical PP242 Sensitive : D	PP242 Sensitive: D – Preclinical PP242 Sensitive : D

Associations
(2)